We help pharma teams build connected drug delivery programmes for inhaled medicines: turning real inhaler use into adherence, technique and real-world evidence. Connected devices, co-developed with Plastiape, run on the regulated Respiro platform behind patient support, clinical studies and market-access dossiers.
What happens between a patient and their inhaler is invisible, and that blind spot works against your therapy on three fronts at once.
Adherence to inhaled medicines is famously low, and technique is often poor, so even the best molecule underperforms when doses are missed, mistimed or mis-taken.
They carry the downstream cost of poorly-controlled disease (exacerbations, emergency visits, admissions) and increasingly want real-world proof of value before they reimburse and keep a therapy on formulary.
They prescribe, then lose sight of what happens at home. Was the dose taken? Taken correctly? Without that picture, they adjust and switch therapies on guesswork, not data.
Connected inhalers turn the lights back on, making everyday use visible as the adherence, technique and real-world evidence every connected drug-delivery programme needs.
Respiro gives patients practical support between visits, gives clinicians a clearer record of treatment use, and gives pharma teams a consented evidence trail that connects adherence, inhalation quality and outcomes.
Help patients stay consistent with treatment through reminders, dose history and simple feedback that fits into daily life.
Turn home use into a clear record of timing, technique and patterns, so treatment decisions are based on what actually happened.
Connect real inhaler use to clinical and economic endpoints, supporting payer discussions with evidence beyond refills and claims.
In Respiro's controlled trial and real-world studies, putting adherence and technique in front of patients improved asthma control, and lowered the downstream cost that payers and providers are measured on. Every figure here is tied to a named study.
Figures come from individual Respiro studies: a cluster RCT (n=68, ERS 2022), a real-world service evaluation (n=59, RDD 2026) and earlier pilots. They describe study populations, not a promise of individual results. Conference results are labelled as such. See the evidence →
Respiro turns real-world inhaler data into evidence you can build on: dose timing and inhalation quality, linked to clinical and economic outcomes, captured by regulated devices.
Every connected dose adds what claims and EHR data cannot: objective evidence of timing and technique, tied to your therapy.
Connect dosing and technique to endpoints so trial teams can see what patients actually did.
Show adherence and inhalation quality evidence that refill, claims and EHR records miss.
Support value-based conversations with evidence that compounds across programmes.
Connected respiratory care isn't a single launch moment. It runs the length of your programme. Respiro and Plastiape support the whole arc: early clinical development, launch in regulated markets, then commercial volume and value-based access.
Use connected-inhaler data in studies to link real dosing and technique to outcomes: fewer unknowns, cleaner endpoints and a better-evidenced path from candidate to approval.
Connected inhalers for trialsBring a connected programme into regulated markets on a medical-device-grade platform, with payer dossiers built on device-linked evidence that claims data cannot provide.
Manufacture connected devices at commercial volume through Plastiape (the inhaler maker behind the RS01, a capsule-DPI platform marketed under multiple brands by multiple pharma companies) and run outcomes-based agreements as the evidence compounds.
Device heritage refers to Plastiape's RS01 inhaler platform; marketed products built on the RS01 are independent third parties, not Amiko partnerships. Outcomes-based access describes a commercial model, not a promise of individual results.
Respiro-connected hardware turns inhaler use into medication-adherence and inhalation-quality data. Co-developed with our device manufacturing partner Plastiape, each route is engineered to be cost-effective and to scale.
Choose a fully integrated route such as RS01X, or use an add-on module for inhalers already selected, launched or familiar to patients, so a connected upgrade fits your device, timeline and routine.
Respiro runs on a medical-device-grade quality system, and the inhaler it connects is built by Plastiape, on a platform pharma already manufactures at commercial scale. De-risked on both sides: the data layer is ours, the supply chain Plastiape's.
Developed under an ISO 13485:2016 QMS on secure cloud infrastructure, with GDPR- and HIPAA-aligned deployments and documentation for EU MDR and US FDA pathways. Where applicable, components carry regional clearances.
Connected devices are made by Plastiape in ISO 7 (Class 10,000) clean rooms, at the commercial volume an inhaled therapy needs, not a pilot line.
The RS01 platform carries a Type III DMF on file with the FDA, regulatory groundwork your own submissions can reference, on a device proven across multiple inhaled-drug programmes.
Clean-room manufacturing and the FDA Drug Master File refer to Plastiape's RS01 inhaler platform; marketed products built on the RS01 are independent third parties, not Amiko partnerships.
Bring together RS01X or add-on hardware, the Respiro platform and Plastiape supply, from early development to outcomes-based access.